A blog that publishes updates and open access scientific papers about allergy, asthma and immunology. Editor: Juan Carlos Ivancevich, MD. Specialist in Allergy & Immunology
September 17, 2017
September 13, 2017
Bacterial d-amino acids suppress sinonasal innate immunity through sweet taste receptors in solitary chemosensory cells
Sci. Signal. Vol 10, Issue 495 05 September 2017
+ See all authors and affiliations
Sci. Signal. 05 Sep 2017:
Vol. 10, Issue 495, eaam7703
DOI: 10.1126/scisignal.aam7703
Vol. 10, Issue 495, eaam7703
DOI: 10.1126/scisignal.aam7703
The sweet taste of bacteria
Stimulation of the sweet taste receptor (T1R) in solitary chemosensory cells of the upper respiratory epithelium inhibits the release of antimicrobial peptides by neighboring epithelial cells. In addition to being activated by various sugars, T1R can also be activated by some D-amino acids.
September 6, 2017
Asthma Control and Sputum Eosinophils: A Longitudinal Study in Daily Practice
Sophie F. Demarche, MPharmCorrespondence information about the author MPharm Sophie F. DemarcheEmail the author MPharm Sophie F. Demarche
,
Florence N. Schleich, MD, PhD
,
Virginie A. Paulus, MLT
,
Monique A. Henket, MLT
,
Thierry J. Van Hees, MPharm, PhD
,
Renaud E. Louis, MD, PhD
Open Access
Background
Longitudinal trials have suggested that asthma control may be influenced by fluctuations in eosinophilic inflammation. This association has however never been confirmed in daily practice.
Fatal Anaphylaxis: Mortality Rate and Risk Factors
Paul J. Turner, MD, PhD
,
Elina Jerschow, MD
,
,
Robert Lin, MD
,
Dianne E. Campbell, MD, PhD
,
Open Access
Up to 5% of the US population has suffered anaphylaxis. Fatal outcome is rare, such that even for people with known venom or food allergy, fatal anaphylaxis constitutes less than 1% of total mortality risk. The incidence of fatal anaphylaxis has not increased in line with hospital admissions for anaphylaxis. Fatal drug anaphylaxis may be increasing, but rates of fatal anaphylaxis to venom and food are stable.
August 27, 2017
A survey on the perception of allergy specialists about the reimbursed grass pollen tablets for seasonal allergic rhinitis in Italy
Clinical and Molecular Allergy
RESEARCH
OPEN ACCESS
Abstract
Background
Sublingual immunotherapy (SLIT) is a feasible option to classical subcutaneous immunotherapy to treat respiratory allergy and is increasingly prescribed in Europe. However, the lack of reimbursement may limit its prescription. In 2015, the 5-grass pollen tablets was authorized by the European Medicine Agency to treat grass-pollen induced rhinitis and was approved in Italy for full reimbursement. We evaluated the opinions of allergy specialists after the availability of the reimbursed 5-grass pollen tablets.
August 26, 2017
The evolving role of tiotropium in asthma
REVIEW
Emma R McIvor,1 R Andrew McIvor2
1Queen’s University, Belfast, UK; 2Department of Medicine, McMaster University, Firestone Institute for Respiratory Health, Hamilton, Ontario, Canada
Abstract: Tiotropium is a long-acting muscarinic antagonist (LAMA) that exerts its bronchodilatory effect by blocking endogenous acetylcholine receptors in the airways. Its safety and efficacy are well established for the treatment of COPD, and it is now being recognized for its role in improving lung function and control in asthma. This review discusses the evolving role of tiotropium delivered by the Respimat® in patients across the range of asthma severities and ages, and provides an overview of safety and efficacy data.
1Queen’s University, Belfast, UK; 2Department of Medicine, McMaster University, Firestone Institute for Respiratory Health, Hamilton, Ontario, Canada
Abstract: Tiotropium is a long-acting muscarinic antagonist (LAMA) that exerts its bronchodilatory effect by blocking endogenous acetylcholine receptors in the airways. Its safety and efficacy are well established for the treatment of COPD, and it is now being recognized for its role in improving lung function and control in asthma. This review discusses the evolving role of tiotropium delivered by the Respimat® in patients across the range of asthma severities and ages, and provides an overview of safety and efficacy data.
August 25, 2017
Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome
SHORT REPORT
OPEN ACCESS
- Hermenio LimaEmail authorView ORCID ID profile,
- Melinda Gooderham,
- Jan Dutz,
- Charles Lynde,
- Hugo Chapdelaine,
- Anne Ellis,
- Martin Gilbert,
- Vincent Ho,
- Kim Papp,
- Yves Poulin and
- Gordon Sussman
© The Author(s) 2017
Abstract
Background
Treat-to-target therapy approaches are established for chronic diseases such as diabetes, hypertension, and more recently rheumatoid arthritis, resulting in improved patient outcomes. These approaches do not use patient reported outcomes (PRO) as targets of therapy. Chronic spontaneous urticaria (CSU), also called chronic idiopathic urticaria (CIU), is defined as recurrent urticaria of known and unknown cause, lasting more than 6 weeks. Treatment of CSU can be challenging. However, with the advent of proven therapies and validated instruments for measuring disease activity, the concept of treat-to-target (T2T) can be successfully applied to CSU. Herein, we propose a potential PRO therapeutic target and suggest a T2T approach for the management of patients with CSU.
August 22, 2017
Could Eosinophilia predict clinical severity in nasal polyps?
- Figen Aslan,
- Eren AltunEmail author,
- Serpil Paksoy and
- Gulay Turan
Multidisciplinary Respiratory Medicine201712:21
© The Author(s). 2017
Abstract
Background
Although nasal polyps are one of the most frequent diseases, their etiopathogenesis remains unclear.Since eosinophils are the main inflammatory cells in the substantial proportion of nasal polyp tissues, they are considered potentially responsible for the etiopathogenesis and prognosis of the disease. Aim of this study was to investigate the relation between mucosal and peripheral eosinophilia and their relation with disease severity in nasal polyps.
Subscribe to:
Posts (Atom)